4.01
0.05 (1.26%)
| Previous Close | 3.96 |
| Open | 3.96 |
| Volume | 20,252 |
| Avg. Volume (3M) | 238,090 |
| Market Cap | 149,555,760 |
| Price / Sales | 40.01 |
| Price / Book | 3.47 |
| 52 Weeks Range | |
| Earnings Date | 15 Sep 2025 - 30 Sep 2025 |
| Operating Margin (TTM) | -3,917.27% |
| Diluted EPS (TTM) | -3.47 |
| Quarterly Revenue Growth (YOY) | -27.40% |
| Total Debt/Equity (MRQ) | 4.68% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | -67.20 M |
| Levered Free Cash Flow (TTM) | -48.03 M |
| Return on Assets (TTM) | -135.31% |
| Return on Equity (TTM) | -263.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Anteris Technologies Global Cor | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 4.13% |
| % Held by Institutions | 64.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| L1 Capital Pty Ltd | 31 Dec 2024 | 2,788,683 |
| One68 Global Capital, Llc | 31 Dec 2024 | 288,914 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jun 2025 | Announcement | Anteris Appoints David Roberts and Gregory Moss to its Board of Directors |
| 13 May 2025 | Announcement | Anteris Announces Results for the First Quarter of 2025 |
| 31 Mar 2025 | Announcement | Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |